protocolSection identificationModule nctId: NCT06359665, orgStudyIdInfo id: HSR230544, briefTitle: Oral Curcumin for the Treatment of Pain of Thumb Base Joint (CMC) Arthritis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Brent DeGeorge, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn about the use of turmeric (Curcumin) as a treatment for pain of thumb-joint arthritis. Turmeric is commonly being used as an over-the-counter treatment for musculoskeletal pain. Clinical trials have demonstrated a pain-relief benefit for knee osteoarthritis, however no clinical trial has been performed to establish efficacy of curcumin in humans for thumb-joint arthritis. The main question\[s\] it aims to answer are:* Is Turmeric more effective than placebo at relieving pain for thumb-joint arthritis? A placebo is a look-alike substance that contains no active drug.* Is Turmeric more effective than placebo at improving patient-reported outcomes for CMC arthritis?* Is Turmeric safe for participants with thumb-joint arthritis?Participants will:* take 4 weeks of daily Turmeric capsules,* take 4 weeks of daily placebo capsules* answer daily surveys about how they are feeling and functioning., conditionsModule conditions: Arthritis of Carpometacarpal Joint of Left Thumb, conditions: Arthritis of Carpometacarpal Joint of Right Thumb, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: The study design will be a double-blind, randomized controlled trial with crossover., primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: Double-blind Randomized Controlled Trial, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Curcumin, interventions name: Placebo, outcomesModule primaryOutcomes measure: Change from Baseline in Pain on the Visual Analog Pain (VAS) Score, primaryOutcomes measure: Change from Baseline in Pain on the Visual Analog Pain (VAS) Score - crossover condition, secondaryOutcomes measure: Change from Baseline in Normal Function on the Single Assessment Numerical Evaluation (SANE) Score, secondaryOutcomes measure: Change from Baseline in Normal Function on the Single Assessment Numerical Evaluation (SANE) Score - crossover condition, secondaryOutcomes measure: Change from Baseline in Quality of Life on the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health-10 Score, secondaryOutcomes measure: Change from Baseline in Quality of Life on the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health-10 Score - crossover condition, secondaryOutcomes measure: Change from Baseline in Pain interference on the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Score, secondaryOutcomes measure: Change from Baseline in Pain interference on the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Score - crossover condition, secondaryOutcomes measure: Change from Baseline in Pain interference on the Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity (UE) Score, secondaryOutcomes measure: Change from Baseline in Pain interference on the Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity (UE) Score, secondaryOutcomes measure: Change from Baseline in Pain on the Australian/Canadian Hand Osteoarthritis (AUSCAN) Index, secondaryOutcomes measure: Change from Baseline in Pain on the Australian/Canadian Hand Osteoarthritis (AUSCAN) Index, secondaryOutcomes measure: Change from Baseline in Disability on The Quick Disability of the Arm, Shoulder (QuickDASH)., secondaryOutcomes measure: Change from Baseline in Disability on The Quick Disability of the Arm, Shoulder (QuickDASH) - crossover condition, secondaryOutcomes measure: Change from Baseline in perseverance on the Brief Resilience Index (BRI), secondaryOutcomes measure: Change from Baseline in perseverance on the Brief Resilience Index (BRI) - crossover condition, secondaryOutcomes measure: Number of Participants With Treatment-Related Adverse Events, secondaryOutcomes measure: Change from Baseline in the Mean Seated Trough Cuff Systolic Blood Pressure, secondaryOutcomes measure: Change from Baseline in heart rate, secondaryOutcomes measure: Change from Baseline in the Mean Seated Trough Cuff Systolic Blood Pressure, secondaryOutcomes measure: Change from Baseline in heart rate, secondaryOutcomes measure: Change from baseline in serum liver panel parameters: Alanine transaminase (ALT), Alkaline phosphatase (ALP) and Aspartate aminotransferase (AST), secondaryOutcomes measure: Change from baseline in serum comprehensive metabolic panel (CMP) parameters: glucose, blood urea nitrogen (BUN), Creatinine, Calcium, secondaryOutcomes measure: Change from baseline in serum comprehensive metabolic panel (CMP) parameters: estimated glomerular filtration rate (eGFR), secondaryOutcomes measure: Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Bilirubin, secondaryOutcomes measure: Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Sodium, Potassium, Chloride, Carbon Dioxide, secondaryOutcomes measure: Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Protein, Albumin, secondaryOutcomes measure: Change from baseline in serum comprehensive metabolic panel (CMP) parameters: Prothrombin time- International normalized ratio (PT-INR), secondaryOutcomes measure: Change from baseline in serum complete blood count (CBC) parameters: Red Blood Cells (CBC), White Blood Cells (WBC), Platelets, secondaryOutcomes measure: Change from baseline in serum complete blood count (CBC) parameters: Hemoglobin, secondaryOutcomes measure: Change from baseline in serum complete blood count (CBC) parameters: Hematocrit, secondaryOutcomes measure: Change from baseline in serum complete blood count (CBC) parameters: Mean Corpuscular Volume (MCV), secondaryOutcomes measure: Change from baseline in serum complete blood count (CBC) parameters: the amount of hemoglobin per red blood cell.(MCH), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False